NCT00585143View on ClinicalTrials.gov

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
Dyslipidemia, Renal Insufficiency
Interventions
DRUG

ABT-335

45 mg once daily for 10 consecutive days

DRUG

Rosuvastatin

10 mg once daily for 10 days

Trial Locations (6)

32608

Site Reference ID/Investigator# 6610, Gainesville

33136

Site Reference ID/Investigator# 6738, Miami

37920

Site Reference ID/Investigator# 7319, Knoxville

55404

Site Reference ID/Investigator# 7723, Minneapolis

78209

Site Reference ID/Investigator# 6928, San Antonio

23298-0160

Site Reference ID/Investigator# 8280, Richmond

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY